BJDX News & Events

Bluejay Diagnostics files to sell 11.22M shares of common stock for holders

Bluejay Diagnostics announced a strategic partnership with Argonaut Manufacturing Services to support the advancement of Bluejay's Symphony platform. This partnership is designed to support Bluejay's broader efforts to establish scalable U.S.-based manufacturing capabilities aligned with its ongoing clinical development programs and future commercialization objectives. In addition, the partnership is intended to strengthen Bluejay's future commercial infrastructure by supporting broader product distribution across the United States, enhancing supply chain resilience, and reducing potential risks associated with international sourcing and import tariffs. The collaboration is also intended to mitigate risks associated with Bluejay's current reliance on overseas manufacturing by establishing domestic manufacturing capabilities that can provide greater operational control, business continuity, and supply chain security. By leveraging U.S.-based manufacturing and distribution capabilities, Bluejay aims to improve operational flexibility, support future market demand, and further enhance its ability to commercialize innovative near-patient diagnostic solutions for critical care settings.

Bluejay Diagnostics announced the enrollment of 624 patients in its ongoing SYMON-II Trial, a pivotal clinical study evaluating the company's Symphony platform for interleukin-6 testing in critical care settings to determine patient acuity for sepsis triage and monitoring. The SYMON-II study has a target enrollment of 750 patients, and the company expects to complete enrollment within the next 2 to 3 months, subject to site activity and patient flow. The SYMON-II trial is designed to support the clinical validation of Bluejay's Symphony IL-6 test, which aims to provide rapid, near-patient results to aid clinicians in assessing patient severity and guiding timely decision-making in acute care environments. With enrollment nearing completion, Bluejay anticipates progressing toward the next phases of clinical validation and regulatory submission activities. The Symphony IL-6 Test to determine patient acuity for sepsis triage and monitoring is currently Bluejay's lead product candidate.

NorthStrive Fund II issued an open letter to the Board of Directors and shareholders of Bluejay Diagnostics, recommending the Board evaluate a strategic opportunity that NorthStrive believes could significantly enhance long-term shareholder value. The company said, "NorthStrive Fund is a significant shareholder of Bluejay and previously disclosed its ownership in a Schedule 13G filed with the U.S. Securities and Exchange Commission on February 5, 2026. In the letter, NorthStrive Fund expressed support for the Board and management team's continued progress advancing the Company's current core program, SYMON II, while encouraging the Company to strengthen its strategic positioning through pipeline expansion capable of introducing additional clinical milestones and value-inflection points. The letter recommends that the Board review the potential acquisition of a Phase-1-ready therapeutic asset targeting refractory chronic cough, a condition affecting millions of patients globally and representing a market opportunity estimated to exceed $10 billion annually. According to NorthStrive Fund, adding a differentiated clinical-stage program could diversify development risk, increase investor visibility, and introduce multiple clinical catalysts that support stronger long-term market valuation. The proposal also notes that financing has been arranged for the potential acquisition through a public-company financing structure, which could support advancement of the program while strengthening the Company's capital position. NorthStrive Fund believes the addition of a differentiated, capital-efficient clinical program capable of delivering near-term milestones could materially strengthen the Company's pipeline and create meaningful upside for shareholders."